发明名称 Rapidly dispersible dosage form of oxcarbazepine
摘要 A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
申请公布号 US9314429(B2) 申请公布日期 2016.04.19
申请号 US201514837493 申请日期 2015.08.27
申请人 APRECIA PHARMACEUTICALS COMPANY 发明人 Jacob Jules;Caputo Kelly;Guillot Micael;Sultzbaugh Kenneth J.;West Thomas G.
分类号 A61K31/55;A61K9/00;A61K9/16;A61K9/20 主分类号 A61K31/55
代理机构 Innovar, L.L.C. 代理人 Matos Rick;Innovar, L.L.C.
主权项 1. A rapidly dispersible solid dosage form comprising a porous non-compressed three-dimensionally printed bound matrix comprising: drug-containing particles having an average, median or mean effective particle size and comprising a first grade of oxcarbazepine (OXC) particles having an average, median or mean first native particle size, a second grade of OXC particles having an average, median or mean second native particle size, at least one disintegrant, at least one surfactant, and at least one binder; at least one disintegrant; and at least one binder; wherein the dosage form disperses in 15 sec or less when placed in 15 ml of aqueous fluid; and the ratio of average, median or mean effective particle size to average, median or mean, respectively, first native particle size ranges from a ratio that is greater than 1:1 to the ratio 5:1, and the ratio of average, median or mean effective particle size to average, median or mean respectively, second native particle size is 20:1 to 50:1.
地址 Langhorne PA US